Do hallucinogens cause residual neuropsychological toxicity?

Hallucinogenic drugs of botanical origin such as psilocybin, DMT, and mescaline have a long history of use, and over the past decades a broad array of synthetic analogues including LSD and MDMA have become widely used. Public health surveys in the 1980s and 1990s documented rising experimental and recreational use among adolescents and young adults, which has fuelled concern about potential long-term adverse effects. Clinical and editorial accounts have been sharply divided, with some authors warning of lasting personality deterioration, chronic psychosis, or organic brain syndromes after repeated exposure, while others have reported low rates of prolonged adverse reactions when drugs were administered in controlled settings. To address this controversy, Halpern and colleagues conducted a systematic review of studies in which formal neuropsychological tests were administered to users of LSD or other hallucinogens. The stated aim was to evaluate the evidence for residual neuropsychological toxicity attributable to hallucinogen use, and to identify methodological weaknesses in the existing literature that limit causal inference and interpretation.

The investigators performed a Medline search from 1 January 1964 to 19 January 1998 using a range of hallucinogen-related search terms (including hallucinogens, LSD, mescaline, psilocybin/psilocin, DMT, and MDMA) and cross-referenced these results with entries for Psychological Tests and Neuropsychological Tests. Initial retrieval counts for individual search terms are reported in the extracted text; pooled searching produced 67 candidate papers, of which 19 explicitly administered neuropsychological tests to hallucinogen users. Reference searching added 23 older sources, bringing the total to 42 investigations under consideration. To focus on residual rather than acute effects, the authors applied five exclusion criteria and retained only studies meeting all requirements. Studies were excluded if testing occurred during acute intoxication; if participants were polydrug users such that hallucinogen-specific effects could not be isolated; if the report consisted only of single case reports or very small case series (fewer than five individuals); if no formal neuropsychological testing was performed; or if the study concerned dissociative agents such as PCP or ketamine. Applying these criteria reduced the eligible literature to nine studies. The review therefore synthesised and compared findings from these nine investigations, noting study designs, sample characteristics, neuropsychological measures, abstinence intervals, and the presence or absence of controls and premorbid data.

Nine qualifying studies were identified, each differing markedly in design, sample selection, and analytic rigour. Sample sizes of hallucinogen-exposed groups ranged from single digits up to about 40 individuals in the studies reviewed. Across the investigations, findings were inconsistent and often limited by methodological weaknesses. One early study compared 21 self-described LSD users with two unmatched control sources (63 psychiatric inpatients and 25 normal volunteers) and reported subtle EEG abnormalities in the LSD group, including increased alpha, beta, delta and theta activity and larger visual evoked response amplitudes at low stimulus intensities. Interpretation was constrained by lack of premorbid testing, unreported lifetime LSD exposure, short minimum abstinence (as little as 48 hours), and no systematic assessment of other substance use. Another controlled study of 30 LSD users matched to 30 controls matched for demographic variables found impaired visuospatial orientation in users and negative correlations between extent of LSD use and performance on Reitan Trail Making Test A and Raven's Matrices; however, other cognitive domains (IQ, concept formation, motor ability, etc.) did not differ, and confounding by recent drug use remained a concern. A psychotherapy cohort study screened 300 candidates and retained 19 subjects with 20 or more LSD ingestions; 16 matched non-exposed controls were chosen. Neuropsychological testing generally showed no significant group differences, though some spatial orientation scores correlated negatively with reported number of LSD exposures and users performed worse on Halstead's category test (nonverbal abstraction). Methodological caveats included frequent prior exposure to multiple other substances among users and at least two subjects reportedly tested while acutely intoxicated. Other reports varied: an uncontrolled series reported no impairment in individuals using LSD for a mean of 12.2 months but lacked premorbid and polydrug data; an inpatient/outpatient neuropsychiatric series found many subjects scoring in the ‘‘brain-damaged’’ range on at least one test but included participants with unknown psychiatric histories and minimal exposure thresholds; and a controlled military-hospital study of 15 users versus 15 controls noted poorer performance on some Reitan battery measures among users but shared similar confounds. A longitudinal university study matched three groups of college students on pre-drug SAT and MMPI scores (no drug history, marijuana-only, and monthly LSD plus marijuana). All groups' test results remained within normal limits, but the LSD group showed significantly worse Trail Making A and B performance at one-year follow-up, with the difference persisting after adjustment for alcohol use. An uncontrolled MDMA case series of nine self-identified users, tested after L-tryptophan infusion, showed no widespread deficits relative to norms but reported Wechsler Memory Scale abnormalities in the Initial Paragraph (44%), Delayed Paragraph (67%), and Delayed Figural (33%) subtests; these scores did not correlate significantly with lifetime MDMA dose in this small sample. Finally, a study of 15 members of a Brazilian religious group who regularly ingest hoasca/ayahuasca (containing DMT plus monoamine oxidase inhibitors) compared with 15 matched controls found better verbal recall on a later learning trial among users and lower scores on novelty-seeking and harm-avoidance personality scales; the UDV's prohibition of other psychoactive substances was noted as a likely factor in these findings. Taken together, the measured results across studies showed occasional findings of EEG changes, visuospatial impairment, deficits on Trail Making tasks, and memory abnormalities, but these findings were neither consistent nor robust across investigations. Importantly, none of the nine studies reported routine toxicological screening to exclude recent use of other substances, abstinence intervals varied widely and sometimes were very short, and premorbid cognitive or psychiatric status was often unassessed. The authors also note that most studies included relatively young subjects and that a majority of participants had used hallucinogens fewer than 50 times, limiting inferences about effects after heavy, long-term exposure.

Halpern and colleagues conclude that the available neuropsychological literature provides little evidence for major, persistent cognitive toxicity from hallucinogen use, and that alarmist predictions from earlier commentaries are not supported by the reviewed data. Although several studies reported isolated deficits—changes in evoked potentials, visuospatial impairments, Trail Making deficits, or memory problems—these observations were not consistently replicated and are tempered by pervasive methodological shortcomings. Key limitations identified by the authors include failure to control for premorbid cognitive and psychiatric differences between users and controls, inadequate assessment or exclusion of past and current use of other illicit drugs and alcohol, inconsistent and sometimes brief abstinence intervals that may allow acute effects to confound residual assessments, and small sample sizes that reduce statistical power. The lack of toxicological screening was emphasised as a major shortcoming. The authors argue that many of these biases would increase the likelihood of false-positive findings (type I error); yet despite such biases, studies generally identified few residual effects, suggesting that large, clinically important impairments are unlikely to have been systematically missed. Nonetheless, a type II error — failing to detect a true residual effect — cannot be excluded. The reviewers note several potential sources of false negatives: the small samples (typically 9–40 hallucinogen users per study) may miss subtle effects that would be important at a population level; study cohorts were predominantly young, whereas neurotoxic effects might emerge or worsen with ageing; many subjects had relatively limited lifetime exposure (fewer than 50 occasions), so deficits after very heavy use could be undetected; and the neuropsychological tests employed might not have targeted the specific cognitive domains vulnerable to hallucinogen-related injury. The authors also discuss theoretical mechanisms that could underlie long-term toxicity, including drug-induced cerebral vasospasm leading to repeated hypoxic events, pharmacologic actions at 5-HT2a/c receptors (shared with pathways implicated in psychotic illness), and interactions with glutamatergic (NMDA) systems. They caution, however, that mechanistic interpretation is limited by incomplete understanding of neurobiological pathways to psychosis and neurodegeneration, and note paradoxical preclinical findings in which some hallucinogens showed protective effects in models of NMDA antagonist toxicity.

The authors recommend that future research address the methodological weaknesses identified in the existing literature. They advise recruiting larger samples of hallucinogen users with extensive lifetime exposure and minimal concomitant psychopathology or other drug use, and carefully matching or controlling for these potential confounders. An ‘‘ideal’’ study should include comprehensive exclusion criteria, routine toxicological screening, and a broad neuropsychological battery—potentially augmented by timed information-processing tasks—to maximise sensitivity and specificity. Recognising the difficulty of finding ‘‘pure’’ hallucinogen users in Western settings, Halpern and colleagues suggest that certain indigenous or religious groups (for example, iboga-using communities in Gabon, Huichol and Tarahumara populations in Mexico, and members of the Native American Church who use peyote) may provide valuable naturalistic cohorts because of extensive botanical hallucinogen use with limited exposure to other drugs. Such studies could be supplemented with non-verbal testing to reduce cultural and language bias and would help clarify the long-term neuropsychological and social consequences of chronic, controlled hallucinogen use.